A wide range of cardiac symptoms have been observed in COVID-19 patients, often significantly influencing the clinical outcome. While the pathophysiology of pulmonary COVID-19 manifestation has been substantially unraveled, the underlying pathomechanisms of cardiac involvement in COVID-19 are largely unknown. In this multicentre study, we performed a comprehensive analysis of heart samples from 24 autopsies with confirmed SARS-CoV-2 infection and compared them to samples of age-matched Influenza H1N1 A (n = 16), lymphocytic non-influenza myocarditis cases (n = 8), and non-inflamed heart tissue (n = 9). We employed conventional histopathology, multiplexed immunohistochemistry (MPX), microvascular corrosion casting, scanning electron microscopy, X-ray phase-contrast tomography using synchrotron radiation, and direct multiplexed measurements of gene expression, to assess morphological and molecular changes holistically. Based on histopathology, none of the COVID-19 samples fulfilled the established diagnostic criteria of viral myocarditis. However, quantification via MPX showed a significant increase in perivascular CD11b/TIE2 + —macrophages in COVID-19 over time, which was not observed in influenza or non-SARS-CoV-2 viral myocarditis patients. Ultrastructurally, a significant increase in intussusceptive angiogenesis as well as multifocal thrombi, inapparent in conventional morphological analysis, could be demonstrated. In line with this, on a molecular level, COVID-19 hearts displayed a distinct expression pattern of genes primarily coding for factors involved in angiogenesis and epithelial-mesenchymal transition (EMT), changes not seen in any of the other patient groups. We conclude that cardiac involvement in COVID-19 is an angiocentric macrophage-driven inflammatory process, distinct from classical anti-viral inflammatory responses, and substantially underappreciated by conventional histopathologic analysis. For the first time, we have observed intussusceptive angiogenesis in cardiac tissue, which we previously identified as the linchpin of vascular remodeling in COVID-19 pneumonia, as a pathognomic sign in affected hearts. Moreover, we identified CD11b + /TIE2 + macrophages as the drivers of intussusceptive angiogenesis and set forward a putative model for the molecular regulation of vascular alterations.
Cardiac manifestations of COVID-19 represent a significantly underappreciated injury pattern in conventionally assessed specimens.
As in other organs, cardiac involvement by COVID-19 is an angiocentric process, which in the heart appears to be primarily driven by macrophages.
Vascular remodeling in the shape of intussusceptive angiogenesis with accompanying microthrombi may explain the observed clinical findings, such as arrhythmia, elevated troponin levels, and reduced ejection fraction.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily affects the respiratory system and may also evolve into a multi-organ disease , with virus-triggered vasculopathy, especially endothelial dysfunction, hypercoaguability, and microthrombi [2, 3] as a common denominator [4, 5] and predictor for disease severity [6,7,8]. Among the plethora of symptoms associated with coronavirus disease 2019 (COVID-19), 20–30% of hospitalized patients show cardiac function impairment with a myocarditis-like presentation . They may suffer from arrhythmia, elevated troponin levels, lower ejection fraction, and ventricle wall dyskinesia . Additionally, right ventricular dysfunction, in part due to increased afterload by pulmonary vascular involvement (e.g., microthrombi and vascular remodeling), is a common finding contributing to increased cardiac serum markers and acts as an independent risk factor for a severe cause of disease and mortality [11,12,13].
While an increasing number of COVID-19 cases with cardiac involvement are being reported, and the possibility of COVID-19-triggered chronic cardiac disease is under discussion, the actual pathomechanisms and sequence of heart injury in the affected patients remain unclear. Similar frequencies of cardiac symptoms in COVID-19 and SARS beta-coronavirus patients suggest a form of heart injury with myocyte damage and residual fibrosis comparable to other forms of viral myocarditis . Unraveling the exact injury mechanism is complicated by the potential impact of preexisting cardiac conditions . Also, cardiac injury, as defined by elevated serum markers such as troponins, is a rather common finding in patients in need of intensive care, regardless of the underlying disease .
Current hypotheses regarding cardiac injury in COVID-19 infection include both direct and indirect injury to the myocardium by viral infection. Cardiac COVID-19 infection has been described in a series of case reports describing clinical (peri-) myocarditis . Thus, SARS-CoV-2 RNA has been reported anecdotally in cardiac tissue and two case reports described virus-shaped particles in cardiac macrophages  and cardiomyocytes . Another hypothesis implicates the systemic release of pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-α, IFN-γ, and MIP) and the subsequent “cytokine storm” as the main culprit with subsequent increased vascular wall permeability and myocardial edema .
Conventional histopathology studies report mixed findings in COVID-19 hearts ranging from typical lymphocytic myocarditis, thrombotic microangiopathy to a lack of significant lymphocytic infiltrates and myocyte damage, with the majority of cases not fulfilling the established Dallas criteria for myocarditis . The most frequently reported morphological finding has been a slight increase in perivascular macrophages, often referred to as borderline myocarditis [19, 22]. Interpreting the results is further hampered by the inconsistency of the used nomenclature regarding the terms myocarditis, inflammation, and cardiac involvement. Here, we decided to define myocarditis in line with the established Dallas criteria as conventional lymphocyte-driven inflammation, compared to macrophage-driven inflammatory reactions in COVID-19 and influenza hearts.
In order to provide a better understanding of the (ultra)structural changes and inflammatory microenvironment in the heart of COVID-19 patients, we employed a multimodal and comprehensive analysis of cardiac autopsy tissue via histology, immunohistochemistry, vascular corrosion casts, electron microscopy, and gene expression analysis using influenza (H1N1) cases, classic viral myocarditis (e.g., coxsackievirus), and non-infected control cases.
Patient selection and workflow
We analyzed cardiac autopsy specimens from 24 patients, who died from respiratory failure caused by SARS-CoV-2 infection and compared them with heart samples from 16 patients, who died from pneumonia caused by influenza A virus subtype H1N1 (A[H1N1])—a strain associated with the 1918 and 2009 influenza pandemics. The influenza samples were selected from archived tissue from Hannover Medical School and RWTH Aachen mainly from the 2009 pandemic as well as from 2010, 2011, and 2018, and chosen for the best possible match regarding age, sex, and disease severity. Eight heart samples of non-influenza and non-SARS-CoV-2 myocarditis were selected from archived tissue from routine diagnostics at Hannover Medical School and autopsy cases from university clinic Augsburg. Nine tissue samples from cardiac surgery other than infectious/inflammatory disease served as uninfected control specimens. The experiments performed were approved by the local ethics committee at Hannover Medical School (ethics vote number: 2893-2015 and 9022 BO K 2020). The COVID-19 group consisted of hearts from nine female and fifteen male patients with mean (± SD) ages of 76 ± 6.3 years and 72 ± 12.8 years, respectively. The influenza group consisted of hearts from seven female and nine male patients with mean (± SD) ages of 53 ± 16.7 years and 51 ± 15.2 years, respectively. The non-influenza and non-SARS-CoV-2 myocarditis group consisted of samples from three female and five male patients with mean (± SD) ages of 59 ± 29.5 years and 52 ± 18.4 years, respectively. The control group consisted of hearts from seven female and two male patients with mean (± SD) ages of 53 ± 20.1 years and 62.5 ± 3.5 years, respectively (patient characteristics and clinical data are provided in supplementary Tables 1 and 2).
Clinical data on cardiac involvement including serum parameters such as CK-MB, troponin, NT-proBNP, and echocardiography data were available in 16 of the 24 analyzed samples in the COVID-19 cohort, 12 of the 16 influenza cases, and 3 of the 8 non-influenza myocarditis cases, respectively. Clinical signs of cardiac involvement were defined by elevated serum markers, e.g., CK-MB, troponin, NT-proBNP, and/or abnormalities in echocardiography, e.g., reduced LVEF/RVEF or dyskinesia, and were found in 11 of the 16 surveyed COVID-19 cases, 9 of the 12 explored influenza cases and all 3 of the myocarditis cases (for full clinical data see supplementary Tables 1 and 2).
Heart samples were comprehensively analyzed, employing the whole spectrum of conventional histopathology, immunohistochemistry, multiplex immunohistochemistry, microvascular corrosion casting, synchrotron radiation tomographic microscopy (SRXTM), and gene expression analysis via the ncounter nanostring system. SARS-CoV-2 detection was performed by immunohistochemistry against SARS-CoV-2 spike and nucleocapsid protein, and the presence of RNA was detected using an RNA-FISH probe and RT-PCR after RNA isolation of FFPE samples. Specifically, from the available formalin-fixed unembedded tissue, 13 COVID-19 samples, 3 lymphocytic myocarditis samples, and 3 control samples were suitable for vascular corrosion casting and 3D scanning electron microscopy, the gold standard for detailed analysis of tissue the microvasculature, angiogenesis, and vascular occlusions, e.g., by microthrombi . Additionally, FFPE paraffin blocks from 11 COVID-19 and 5 control heart samples were investigated by phase-contrast X-ray tomography at the GINIX endstation of the P10 beamline at the PETRAIII storage ring 104 (DESY, Hamburg), a novel technique for assessing especially the capillary network, recently demonstrated by us . A detailed description of the employed methods can be found in supplementary methods (Supplementary files, supplementary methods).
Mononuclear inflammatory response in COVID-19 cardiac tissue
Conventional light microscopy of COVID-19 heart samples showed minor inflammatory infiltrates consisting mainly of macrophages in only 1 of 24 cases. The Influenza group showed no significant inflammatory infiltration in all 16 analyzed cases using light microscopy. In contrast, non-influenza/non-SARS-CoV-2 myocarditis cases revealed lymphocytic infiltrates, with minor infiltrates in 4 of the 8 cases, severe lymphocytic infiltrates in 3 of the 8 cases and 1 of the 8 cases with only minimal sparse inflammatory infiltrate with adjacent single-cell necrosis, all but one fulfilling the Dallas criteria for myocarditis (Fig. 1A), while no necrosis was observed in COVID-19, influenza or control tissue. Regarding interstitial fibrosis, no statistically significant (Chi-square test p = 0.45) difference was found between the four groups, with COVID-19 (mean score 0.85) displaying the highest and the Influenza group (mean score 0.6) displaying the lowest fibrotic remodeling, respectively (Fig. 1A, B). Cardiomyocyte hypertrophy was most pronounced in the COVID-19 group (mean score 1.2), followed by control cases (mean score 1.1), and with influenza (mean score 0.4) and common viral myocarditis cases (mean score 0.8) showing the least amount of hypertrophy (combined Chi-square test p < 0.0001). However, COVID-19 patients were statistically significantly older (73.7 ± 10.8 years) compared to influenza (52.3 ± 15.3 years, p < 0.001), common myocarditis (54.8 ± 21.3; p < 0.05), and non-inflamed control patients (54.9 ± 18.0, p < 0.05). Immunohistochemistry for SARS-CoV-2 spike and nucleocapsid protein as well as RNA-FISH for SARS-CoV-2 RNA showed no specific signal in the analyzed COVID-19 tissues. However, RT-PCR for SARS-CoV-2 RNA yielded positive results in 17 of the 24 analyzed samples (supplementary Table 1).
A more detailed analysis of the inflammatory cell composition showed a marked increase of macrophages (CD68 +) in all infectious groups compared to controls, with influenza cases displaying the most prominent infiltrate (130.2 ± 1.0) with a twofold higher number of macrophages per mm2 compared to COVID-19 (65.2 ± 0.8) and common myocarditis (72.5 ± 1.6) (Fig. 2, supplementary table 3). Lymphocytic (CD4, CD8, CD20) infiltrates were scarce in both COVID-19 and influenza cases, whereas common myocarditis cases displayed—besides the prominent macrophage infiltrate—a marked mixed lymphocytic inflammatory infiltrate (Fig. 2, supplementary table 3).
CD11b + /TIE2 + monocytes/macrophages in COVID-19
Macrophages were the predominant inflammatory cell type in both COVID-19 and influenza cases (Fig. 3A). Regarding macrophage subpopulations, a shift towards an M2 phenotype as indicated by the significant increase in CD16 + CD163 + macrophages in COVID-19 (141.4 ± 129.3 cells per mm2) and lymphocytic non-influenza myocarditis (1112.8 ± 1683.4 cells per mm2) when compared to influenza (32.6 ± 34.6 cells per mm2). Other marker combinations (CD16- CD163 + and CD16 + CD163 + S100A9 + , respectively) did not yield significant differences (Supplemental Table 3). We found a diffuse infiltration of CD11b + -macrophages in the perivascular connective tissue in 18 of 24 COVID-19 heart samples (Fig. 3A, B, supplementary Table 3) to a varying degree. As expected, CD11b expression was found primarily on monocytes and perivascular macrophages (Fig. 3A). As we could find a higher expression of TIE2 (TEK) in COVID-19 compared to influenza, non-influenza viral myocarditis, and control samples by nanostring analysis, we performed additional immunohistochemical stains demonstrating TIE2 expression primarily on macrophages (supplementary Fig. 1). TIE2-expressing macrophages (TieMs) were present at a significantly higher level in COVID-19 samples (0.7 ± 0.2 cells per mm2; Fig. 3C) compared to influenza samples (0.22 ± 0.108 cells per mm2; Fig. 3D) and control samples (0.27 ± 0.07 cells per mm2, Fig. 3D). Furthermore, immunohistochemical presence of TieMs was elevated more than fivefold in hearts from COVID-19 patients hospitalized later than 10 days after the detection of the infection (1.9 ± 0.6 cells per mm2, Fig. 3D) compared to COVID-19 patients hospitalized earlier (0.4 ± 0.1 cells per mm2, Fig. 3D). This is supported by an increased expression of Angiopoietin 2 in COVID-19 hearts on a gene expression level (Fig. 4) as well as on protein level, detected by IHC (supplementary Fig. 1), compared to controls.
Vascular remodeling by intussusceptive angiogenesis contributes to cardiac adverse repair in COVID-19 microangiopathy
Using conventional light microscopy and immunohistochemical staining for fibrin, only scarce small vessel thrombi and no large vessel thrombi could be demonstrated in COVID-19 hearts (Fig. 1A), while two heart samples in the influenza group showed large vessel thrombi without thrombi in small vessels (Fig. 5A–C). Interestingly, contrary to the light microscopy findings, SEM imaging of corrosion casts of COVID-19 hearts showed a marked increase in the presence of ultrastructurally detectable thrombi (uTH), as indicated by abrupt breakoff of capillaries (Fig. 5D and Fig. 6A). These capillaries had a diameter of 1–3 µm, too small to be reliably detectable in conventional light microscopy, especially in autopsy material. Moreover, COVID-19 hearts showed an altered vascular architecture with a loss of vascular hierarchy, tortuous arrangement (Fig. 6A), and irregular sinusoidal vessel networks with frequent vessel diameter changes compared to the paralleled alignment of cardiac microvascularity in the healthy controls (compare Fig. 6B, D). Furthermore, the presence of transluminal intussusceptive pillars indicated by small holes in vascular corrosion casts (Fig. 5E and Fig. 6D), partly as doublets and triplets, at numerous vessel branches (Fig. 6D), could be found in COVID-19 hearts, but not in non-influenza myocarditis cases. Quantification of corrosion casts proved that non-influenza viral myocarditis cases had significantly fewer intussusceptive pillars (2.8 ± 3.7 SE) and uTh (0.1 ± 1.0 SE) compared to COVID-19 hearts (9.4 ± 1.0 SE and 2.3 ± 0.3 SE, respectively, Fig. 5F). Of note, we found a positive correlation between the presence of microthrombi and the occurrence of intussusceptive pillars in COVID-19 hearts (Fig. 5G). Corrosion casts of control hearts did not show signs of uTH or intussusceptive pillars (Fig. 6B). Archived material of the 2009 influenza pandemic suitable for corrosion casting was not available.
Phase-contrast synchrotron radiation tomographic microscopy (SRXTM) identified the spatial coincidence of morphological aspects of disturbed, feathered course of heart fibers, mild interstitial fibrosis, and the occurrence of intussusceptive pillars (Fig. 6E). Moreover, volume segmentation of SRXTM tomographs demonstrated vascular alterations in COVID-19 hearts at the level of the afferent, large-caliber vessels (Fig. 6F), compared to regular vascular architecture in the analyzed control tissue.
Differential regulation of myocardial mRNA expression and associated biological functions in COVID-19, influenza, and myocarditis
We performed a digital multiplexed gene expression analysis using NanoString nCounter® technology. In COVID-19 hearts, we identified significant upregulation of pro-inflammatory genes IL1B, IL-6, IL8, and the toll-like receptor TLR2 (Fig. 4). Moreover, significant upregulation of hypoxia and angiogenesis-related genes as documented by VEGFC, FLT1, and NOS3 was found (Fig.4, FDR < 0.05). Gene expression analysis showed a significant upregulation of genes associated with monocyte recruitment such as CXCR4, MMP9, CCR2, CXCR2, and MYD88 (Fig. 4, FDR < 0.001). Moreover, cell adhesion markers such as ICAM1, PECAM1, and SELE were markedly, and significantly, upregulated in COVID-19, influenza, and non-influenza viral myocarditis (Fig. 4, FDR < 0.001). TIE2 was not ubiquitously upregulated in COVID-19, influenza, and non-influenza viral myocarditis compared to controls, but 10 of the 24 COVID-19 hearts displayed a marked upregulation of up to tenfold (supplementary material).
In addition to canonical pathways, differentially expressed genes were categorized to related functional pathways via gene set enrichment analysis against the Gene Ontology (GO) aspect biological functions. A complete list of GO annotations and a complete list of the analyzed genes is given in the Supplementary material. Gene expression data analysis of 797 analyzed genes showed clear differences between COVID-19 and influenza cases, but not between COVID-19 cases and non-influenza lymphocytic myocarditis (Fig. 7A). While influenza cases were primarily characterized by pro-inflammatory signaling and classical anti-viral response gene expression (e.g., BCL6, DLL4, GDF15, PTX3, HMGB2, and IL-8). COVID-19-associated gene expression showed significant upregulation of angiogenesis, cell migration, and epithelial-mesenchymal-transition (EMT) pathways in the ingenuity pathway analysis (Fig. 7B).
Comparative gene analysis demonstrated twice as much differentially expressed genes in COVID-19 compared to influenza (152 genes in COVID-19 vs 72 genes in Influenza) (Fig. 7C).
We previously reported a prominent vasculocentric inflammation and its sequelae in COVID-19 lung injury , which result from direct injury of the pulmonary endothelium. Here, for the very first time, we comprehensively assessed and compared the molecular, morphological, and ultrastructural aspects of injury patterns in cardiac tissue of patients, who succumbed to COVID-19, influenza and non-influenza lymphocytic myocarditis. We propose that a similar vascular tropism  with subsequent endothelial damage resulting in marked alterations of the cardiac microvasculature, including an increased number of uTh and local hypoxia, characterize the cardiac involvement in COVID-19 (Fig. 8).
COVID-19-associated cardiac injury is discussed as both direct and indirect injury to the myocardium. Although cardiomyocytes express significant levels of ACE2, which serves as SARS-CoV-2 receptor , the lack of TMPRSS2, a cell-membrane-based protease needed for conformation changes in the spike protein of SARS-CoV-2 and cell membrane fusion , likely hampers direct cardiomyocyte infection. Another hypothesis for the cardiac involvement in COVID-19 implicates the systemic release of pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-α, IFN-γ, and MIP) and the subsequent “cytokine storm” as the main culprit with subsequent increased vascular wall permeability and myocardial edema . Consistently, we found signs of endothelial damage and endothelial activation in the form of increased gene expression pathways regarding EMT/EndoMT in COVID-19 hearts accompanied by an upregulation of tissue hypoxia-related pathways and the formation of uTh. Here, it should be noted that in our study, EMT might rather reflect EndoMT, two largely overlapping pathways with the latter not reflected in Ingenuity`s pathway analysis [25, 26].
Vascular injury and tissue hypoxia lead to an activation of local macrophages  and drive transcriptional profiles associated with the recruitment of circulating monocytes in COVID-19, as documented by the observed marked increase in tissue macrophages and the upregulation of CCR2, CYCR2, CXCR4, and MYD88. The recruitment of bone marrow-derived mononuclear cells has been identified in a variety of cardiovascular diseases, including atrial fibrillation , myocardial infarction , and heart failure , but also in cardiac fibrosis  and extra cardiac diseases, e.g., bronchiolitis obliterans in the lung . Monocyte recruitment is also supported by tissue-resident CCR2 + macrophages—especially CXCR4 + /CD11b + monocytes via MYD88-dependent and SDF-1/CXCR4 pathway-associated mechanisms, resulting in a release of inflammatory cytokines. Additionally, monocytes are hypothesized to be involved in angiogenesis either via the depletion of proangiogenic growth factors (e.g., VEGF, FGF2, or eNOS) or by mimicking endothelial progenitor cells (EPCs) and becoming incorporated as endothelial cells . Our transcriptional data provide evidence that significantly higher levels of hypoxia-related and proangiogenic genes (HIF1a, VEGFA, FGF2, eNOS, SOX17, and LRG1) promote neovascularization at the site of increased cardiac ischemia.
Thus, macrophages are the main responders involved throughout the pathomechanistic sequence , from recruitment of circulating monocytes over the mediation of cardiac inflammation, to irreversible tissue remodeling of the fibrovascular interface in the form of intussusceptive angiogenesis.
Pronounced neovascularization in form of CD11b/TIE2 +—macrophage associated intussusceptive angiogenesis, as previously described in other organs , has been our most intriguing observation in cardiac remodeling triggered by SARS-CoV-2 infection.
Intussusceptive (non-sprouting) angiogenesis is a highly dynamic process observed within minutes to hours after a stimulus without requiring cell proliferation  and is described also in the early phases of the disease in COVID-19 lungs . In this process, the formation of a transluminal pillar is crucial for the duplication and expansion of the vascular plexus. Intussusceptive angiogenesis and similar hemodynamic alterations have previously been observed in atherosclerosis , inflammatory diseases , malignancies , and in parvovirus B19 viral myocarditis . Additionally, intussusceptive angiogenesis plays a pivotal role in fibrotic remodeling, for example in interstitial lung diseases  as well as in protection against prothrombotic endothelial dysfunction in COVID-19 .
The molecular and mechanical factors involved in the rapid expansion of intussusceptive angiogenesis are, thus, far poorly understood, in part, because in vitro models for intussusception are missing. However, it is known that SDF-1/CXCR4 signaling is involved in the blood vessel formation and remodeling by intussusception . In a parabiosis model, we previously reported that blood-borne migrating CD11b + monocytes significantly contribute to lung regeneration and angiogenesis via intussusception . Mechanistically, this occurs via SDF-1 mediating the arrest of CD34 + endothelial progenitor cells on the vascular endothelium under shear flow by the action of the integrins VCAM and ICAM . TIE2-expressing cells then promote the incorporation, maturation, and vascular stabilization of the bone marrow-derived monocytes . Growing evidence implicates a pivotal role for the SDF-1/CXCR4 axis in myocardial repair, especially in myoangiogenesis, characterized by recruitment and engraftment of bone marrow-derived mononuclear cells after acute myocardial infarction , in cardiomyopathy , and negatively predicting mortality in viral myocarditis . Our results support these findings by identifying a significant infiltrate of CD11b + /TIE2 + macrophages with concurrent increased intussusceptive angiogenesis and a significant upregulation of CXCR4, SDF-1, and MMP9.
It should be noted that our study has some limitations. In the literature, Tie-2 is described as a marker of endothelial cells. However, the antibody clone we used worked on a subset of macrophages but not consistently on endothelial cells of the autopsy material likely due to autolysis artifacts. Due to technical shortcomings, detailed cardiovascular parameters were not available for all patients, and not all analyses could be performed on each case. For technical reasons, ultrastructural analysis is feasible only in larger tissue samples from autopsies, thus, restricting our study to patients with intensive care treatment and fatal outcomes. Additionally, the COVID-19 cohort was significantly older, which potentially influenced parameters such as cardiac fibrosis or hypertrophy. Lastly, due to a limited cohort size as well as incompletely reported clinical findings, consistent conclusions on individual attributability cardiac symptoms to underlying molecular alterations were unfeasible. Despite these restrictions, our results define a distinct and novel cardiac manifestation of severe COVID-19.
To summarize, our findings suggest that (I) cardiac involvement in COVID-19 does not present as conventional viral myocarditis defined by mononuclear infiltrates and myocyte damage, but rather as a perivascular infiltration by a special subpopulation of CD11b + /TIE2 + macrophages contributing to cardiac neoangiogenesis and remodeling of the fibrovascular interface. (II) COVID-19 cardiac involvement is substantially underappreciated in conventional light microscopy and its adequate diagnosis requires a multimodal approach. (III) Our comparative morphological and transcriptional data indicate that the irreversible remodeling due to intussusceptive angiogenesis—based on our experience in other organs—is the main driver for a specific COVID-19-induced cardiac injury. It is facilitated by interactions between the incorporated of blood-borne CD11b + /TIE2 + monocytes/macrophages and damaged and activated endothelial cells in COVID-19 hearts (Fig. 8). A systematic follow-up of non-fatal COVID-19 and long-COVID cases appear highly warranted for the detection of possible post-acute cardiac symptoms and fibrotic remodeling also in mild cases of disease due to the irreversible alterations of the cardiac vasculature.
Additional Data will be made available on reasonable request.
Angiotensin-converting enzyme 2
B-cell lymphoma 6
Bone marrow dendritic cells
Bone marrow-derived mononuclear cells
C–C chemokine receptor type 2
Cluster of differentiation molecule 4
Cluster of differentiation molecule 8
Cluster of differentiation molecule 11b
Cluster of differentiation molecule 16
Cluster of differentiation molecule 20
Cluster of differentiation molecule 34
Cluster of differentiation molecule 68
Cluster of differentiation molecule 163
Creatine kinase myocardial band
Coronavirus disease 2019
C-X-C motif chemokine 12
C-X-C chemokine receptor type 2
C-X-C chemokine receptor type 4
Delta-like canonical notch ligand 4
- E gene:
Encoding envelope protein
Endothelial progenitor cells
Elastica van giesson
False discovery rate
Fibroblast growth factor 2
Fluorescence in situ hybridization
Fms-related receptor tyrosine kinase 1
Growth/differentiation factor 15
Hematoxylin and Eosin
Hypoxia-inducible factor 1-alpha
High-mobility group box 2
Intercellular adhesion molecule 1
Intensive care unit
Interleukin 1 beta
Leucine-rich alpha-2-glycoprotein 1
Left ventricular ejection fraction
Macrophage inflammatory proteins
Matrix metallopeptidase 9
Magnetic resonance imaging
Messenger ribonucleic acid
Myeloid differentiation primary response 88
Nitric oxide synthase 3
N-terminal prohormone of brain natriuretic peptide
Periodic acid schiff
Polymerase chain reaction
Platelet and endothelial cell adhesion molecule 1
Regions of interest
Reverse transcription polymerase chain reaction
Right ventricular ejection fraction
S100 calcium-binding protein A9
Severe acute respiratory syndrome coronavirus type 2
Stromal cell-derived factor 1
Scanning electron microscope
SRY-box transcription factor 17
Synchrotron radiation tomographic microscopy
Toll-like receptor 2
Transmembrane protease serine subtype 2
Tumor necrosis factor alpha
Ultrastructurally detectable thrombi
Vascular cell adhesion molecule
Vascular endothelial growth factor A
Vascular endothelial growth factor C
Gupta A, Madhavan MV, Sehgal K et al (2020) Extrapulmonary manifestations of COVID-19. Nat Med 26:1017–1032. https://doi.org/10.1038/s41591-020-0968-3
Smadja DM, Mentzer SJ, Fontenay M et al (2021) COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Springer, Netherlands
Rovas A, Osiaevi I, Buscher K et al (2021) Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis 24:145–157. https://doi.org/10.1007/s10456-020-09753-7
Ackermann M, Verleden SE, Kuehnel M et al (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 383:120–128. https://doi.org/10.1056/NEJMoa2015432
Libby P, Lüscher T (2020) COVID-19 is, in the end, an endothelial disease. Eur Heart J 41:3038–3044. https://doi.org/10.1093/eurheartj/ehaa623
Philippe A, Gendron N, Bory O et al (2021) Von willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance. Angiogenesis 24:407–411. https://doi.org/10.1007/s10456-021-09789-3
Philippe A, Chocron R, Gendron N et al (2021) Circulating von willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis 24:505–517. https://doi.org/10.1007/s10456-020-09762-6
Smadja DM, Guerin CL, Chocron R et al (2020) Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis 23:611–620. https://doi.org/10.1007/s10456-020-09730-0
Basso C, Leone O, Rizzo S et al (2020) Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J 41:3827–3835. https://doi.org/10.1093/eurheartj/ehaa664
Weckbach LT, Curta A, Bieber S et al (2021) Myocardial inflammation and dysfunction in COVID-19-associated myocardial injury. Circ Cardiovasc Imaging. https://doi.org/10.1161/CIRCIMAGING.120.011713
Ghidini S, Gasperetti A, Winterton D et al (2021) Echocardiographic assessment of the right ventricle in COVID-19: a systematic review. Int J Cardiovasc Imaging 37:3499–3512. https://doi.org/10.1007/s10554-021-02353-6
Goudot G, Chocron R, Augy JL et al (2020) Predictive factor for COVID-19 worsening: insights for high-sensitivity troponin and D-dimer and correlation with right ventricular afterload. Front Med 7:1–11. https://doi.org/10.3389/fmed.2020.586307
Moody WE, Mahmoud-Elsayed HM, Senior J et al (2021) Impact of right ventricular dysfunction on mortality in patients hospitalized with COVID-19, according to race. CJC Open 3:91–100. https://doi.org/10.1016/j.cjco.2020.09.016
Yu C-M, Wong RS-M, Wu EB et al (2006) Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J 82:140–144. https://doi.org/10.1136/pgmj.2005.037515
Basu-Ray I, Almaddah NK, Adeboye A, Soos MP (2021) Cardiac manifestations of coronavirus (COVID-19). StatPearls, Treasure Island
Edouard AR, Felten ML, Hebert JL et al (2004) Incidence and significance of cardiac troponin I release in severe trauma patients. Anesthesiology 101:1262–1268. https://doi.org/10.1097/00000542-200412000-00004
Halushka MK, Vander Heide RS (2021) Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc Pathol. https://doi.org/10.1016/j.carpath.2020.107300
Tavazzi G, Pellegrini C, Maurelli M et al (2020) Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail 22:911–915. https://doi.org/10.1002/ejhf.1828
Albert CL, Carmona-Rubio AE, Weiss AJ et al (2020) The enemy within: sudden-onset reversible cardiogenic shock with biopsy-proven cardiac myocyte infection by severe acute respiratory syndrome coronavirus 2. Circulation 142:1865–1870. https://doi.org/10.1161/CIRCULATIONAHA.120.050097
Zeng JH, Liu YX, Yuan J et al (2020) First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection 48:773–777. https://doi.org/10.1007/s15010-020-01424-5
Thomas Aretz H (1987) Myocarditis: the dallas criteria. Hum Pathol 18:619–624. https://doi.org/10.1016/S0046-8177(87)80363-5
Halushka MK, Vander RS (2020) Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc Pathol. https://doi.org/10.1016/j.carpath.2020.107300
Walsh C, Tafforeau P, Wagner W et al (2021) Hierarchical phase-contrast tomography bridges the gap between intact human organ and cellular scale imaging. bioRxiv. https://doi.org/10.1101/2022.07.02.498430
Liu F, Han K, Blair R et al (2021) SARS-CoV-2 infects endothelial cells In vivo and in vitro. Front Cell Infect Microbiol 11:1–13. https://doi.org/10.3389/fcimb.2021.701278
Chen P, Simons M (2016) When endothelial cells go rogue. EMBO Mol Med 8:1–2. https://doi.org/10.15252/emmm.201505943
Potenta S, Zeisberg E, Kalluri R (2008) The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer 99:1375–1379. https://doi.org/10.1038/sj.bjc.6604662
Yakupova EI, Maleev GV, Krivtsov AV, Plotnikov EY (2022) Macrophage polarization in hypoxia and ischemia/reperfusion: insights into the role of energetic metabolism. Exp Biol Med. https://doi.org/10.1177/15353702221080130
Shahid F, Lip GYH, Shantsila E (2018) Role of monocytes in heart failure and atrial fibrillation. J Am Heart Assoc 7:1–17. https://doi.org/10.1161/JAHA.117.007849
Fraccarollo D, Neuser J, Möller J et al (2021) Expansion of cd10neg neutrophils and cd14+ hla-drneg/low monocytes driving proinflammatory responses in patients with acute myocardial infarction. Elife 10:e66808
Kawaguchi M, Takahashi M, Hata T et al (2011) Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 123:594–604. https://doi.org/10.1161/CIRCULATIONAHA.110.982777
Bröcker V, Länger F, Fellous TG et al (2006) Fibroblasts of recipient origin contribute to bronchiolitis obliterans in human lung transplants. Am J Respir Crit Care Med 173:1276–1282. https://doi.org/10.1164/rccm.200509-1381OC
Shantsila E, Watson T, Lip GYH (2007) Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 49:741–752. https://doi.org/10.1016/j.jacc.2006.09.050
Merad M, Martin JC (2020) Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 20:355–362. https://doi.org/10.1038/s41577-020-0331-4
Ackermann M, Stark H, Neubert L et al (2020) Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases. Eur Respir J. https://doi.org/10.1183/13993003.00933-2019
Mentzer SJ, Konerding MA (2014) Intussusceptive angiogenesis: expansion and remodeling of microvascular networks. Angiogenesis 17:499–509. https://doi.org/10.1007/s10456-014-9428-3
Napoli C, Ignarro LJ (2009) Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res 32:1103–1108. https://doi.org/10.1007/s12272-009-1801-1
Ackermann M, Tsuda A, Secomb TW et al (2013) Intussusceptive remodeling of vascular branch angles in chemically-induced murine colitis. Microvasc Res 87:75–82. https://doi.org/10.1016/j.mvr.2013.02.002
Pandita A, Ekstrand M, Bjursten S et al (2021) Intussusceptive angiogenesis in human metastatic malignant melanoma. Am J Pathol 191:2023–2038. https://doi.org/10.1016/j.ajpath.2021.07.009
Ackermann M, Wagner WL, Rellecke P et al (2020) Parvovirus B19-induced angiogenesis in fulminant myocarditis. Eur Heart J 41:1309. https://doi.org/10.1093/eurheartj/ehaa092
Schmaier AA, Pajares Hurtado GM, Manickas-Hill ZJ et al (2021) Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19. JCI Insight. https://doi.org/10.1172/jci.insight.151527
Dimova I, Karthik S, Makanya A et al (2019) SDF-1/CXCR4 signalling is involved in blood vessel growth and remodelling by intussusception. J Cell Mol Med 23:3916–3926. https://doi.org/10.1111/jcmm.14269
Chamoto K, Gibney BC, Lee GS et al (2013) Migration of CD11b+ accessory cells during murine lung regeneration. Stem Cell Res 10:267–277. https://doi.org/10.1016/j.scr.2012.12.006
Peled A, Grabovsky V, Habler L et al (1999) The chemokine SDF-1 stimulates integrin-mediated arrest of CD34+ cells on vascular endothelium under shear flow. J Clin Invest 104:1199–1211. https://doi.org/10.1172/JCI7615
Thomas M, Augustin HG (2009) The role of the angiopoietins in vascular morphogenesis. Angiogenesis 12:125–137. https://doi.org/10.1007/s10456-009-9147-3
Penn MS (2009) Editorial: Importance of the SDF-1: CXCR4 axis in myocardial repair. Circ Res 104:1133–1135. https://doi.org/10.1161/CIRCRESAHA.109.198929
Zisa D, Shabbir A, Mastri M et al (2011) Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair. Am J Physiol - Hear Circ Physiol 301:2422–2432. https://doi.org/10.1152/ajpheart.00343.2011
Zuern CS, Walker B, Sauter M et al (2015) Endomyocardial expression of SDF-1 predicts mortality in patients with suspected myocarditis. Clin Res Cardiol 104:1033–1043. https://doi.org/10.1007/s00392-015-0871-y
The authors would like to acknowledge Regina Engelhardt, Christina Petzold, Annette Müller-Brechlin, Nicole Krönke, and Kerstin Bahr for their excellent technical support and Nikki Chapman and Edwin Busch for editing the manuscript.
Open Access funding enabled and organized by Projekt DEAL. NIH Grant HL94567, HL134229 to Maximilian Ackermann and Steven J. Mentzer. The grant of the European Research Council (ERC); European Consolidator Grant, XHale to Danny Jonigk (ref. no.771883). This work was supported by the German Research Foundation (Clinical Research Unit [KFO311] to J.D.S, D.J., J.B., K.C.W., and T.K.). A.T. and J.D.H. were supported by the Botnar Research Centre for Child Health (BRCCH), Grant Nr: FTC-2020-10. This work was supported by the German Registry of COVID-19 Autopsies (DeRegCOVID, www.DeRegCOVID.ukaachen.de; supported by the Federal Ministry of Health—ZMVI1-2520COR201), and the Federal Ministry of Education and Research as part of the Network of University Medicine (DEFEAT PANDEMIcs, 01KX2021). PB is supported by the German Research Foundation (Deutsche Forschungsgemeinschaft—DFG; Project IDs 322900939, 454024652, 445703531), the European Research Council (ERC; Consolidator Grant AIM.imaging.CKD, grant agreement No 101001791), and the Federal Ministry of Education and Research (STOP-FSGS-01GM1901A). TS is supported by the German Research Foundation (DFG) under Germany’s Excellence Strategy -EXC 2067/1-390729940.
Conflict of interest
All contributing authors declare no conflict of interest regarding this manuscript.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Werlein, C., Ackermann, M., Stark, H. et al. Inflammation and vascular remodeling in COVID-19 hearts. Angiogenesis 26, 233–248 (2023). https://doi.org/10.1007/s10456-022-09860-7